


RECEIVED
CENTRAL FAX CENTER

SEP 24 2004

**Fax****To:** Examiner David Lukton**From:** Timothy J. Douros

Tel: 781 860 8660

Fax: 781 860 1407

Fax: 703 872 9306**Pages:** 77 (including cover sheet)**Phone:** 571 272 0952**Date:** September 24, 2004**Re:** US Serial No. 09/737,908 (C059 US)**CC:**☐ Urgent ☒ For Review ☐ Please Comment ☐ Please Reply ☐ Please Recycle● **Comments:**

I hereby certify that this correspondence (Response to Restriction Requirement) is being sent via Facsimile to 703 872 9306 for the attention of Examiner David Lukton at Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 24, 2004.

A handwritten signature in black ink, appearing to read "Timothy J. Douros".
Timothy J. DourosA handwritten signature in black ink, appearing to read "Timothy J. Douros".
September 24, 2004
Signature Date

THIS FAX IS FOR THE SOLE USE OF THE INTENDED RECIPIENT(S) AND CONTAINS CONFIDENTIAL AND PRIVILEGED INFORMATION. ITS CONTENTS SHOULD NOT BE DISCLOSED NOR SHOULD IT BE GIVEN OR COPIED TO ANYONE. IF YOU ARE NOT THE INTENDED RECIPIENT, PLEASE CONTACT THE SENDER AND DESTROY ALL COPIES OF THE ORIGINAL MESSAGE. THANK YOU.

C059 US Resp to 082404 OA Fax Cover

65 Hayden Avenue, Lexington, MA 02421

P. 781.860.8660

F. 81.860.1407

www.cubist.com

SEP 24 2004

002

Attorney Docket No. C059

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : David Lukton
Group : 1653
Applicants : Jason Hill et al.
Application No. : 09/737,908
Filed : December 15, 2000
For : NOVEL LIPOPEPTIDES AS ANTIBACTERIAL AGENTS

Mail Stop Non Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This Response is filed in response to the Office Action mailed August 24, 2004 in the above-identified application. Applicants hereby elect the claims of Group 2 for examination on the merits.

Kindly amend the application as follows:

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph on page 81, line 217 through page 821, line 12 as follows:

Antibacterial agents and classes thereof that may be co-administered with a compound of the present invention include, without limitation, penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin,